A material transfer agreement is required whenever tangible, non-public research materials — cell lines, plasmids, antibodies, reagents, transgenic organisms, or associated data — move between two separate legal entities and the provider wants to retain ownership, control future use, or protect intellectual property. If the material is freely purchasable on the open market, or if it never leaves the same legal entity, no material transfer agreement is needed. Between those two extremes sits a middle case — a simple loan or implementing letter — that many institutions handle incorrectly, which is the gap this framework closes.
A material transfer agreement (MTA) is a legally binding contract that sets out the terms under which tangible research materials are supplied by one organisation (the provider) and used by another (the recipient), covering ownership, permitted use, publication rights, liability, and the treatment of any resulting inventions.
Contents
- What is a material transfer agreement?
- When is a material transfer agreement required?
- The decision framework: full MTA, simple letter, or no agreement
- Answer-first Q&A
- Implications for research administrators
What is a material transfer agreement?
A material transfer agreement is the contract vehicle research institutions use to move physical research materials — rather than data or funding — between organisations while preserving each party’s rights. It typically fixes four things: who owns the original material, what the recipient may do with it, who owns anything invented using it, and whether results can be published without restriction.
MTAs sit alongside, but are distinct from, confidentiality agreements and sponsored-research agreements. A confidentiality agreement protects information; an MTA protects a physical or biological thing. Where data accompanies the material — sequencing reads, patient metadata, assay results — many institutions issue a linked Data Transfer Agreement (DTA) rather than folding data terms into the MTA itself.
When is a material transfer agreement required?
An MTA is required whenever three conditions are all true: the item is tangible (not purely information), it is not freely available for anyone to buy, and the provider wants to attach conditions to its use. Absent any one of those three, a lighter mechanism — or nothing — usually suffices.
The general triggers
Institutions typically require a full MTA for: proprietary cell lines and plasmids; genetically modified organisms; patient- or human-derived samples; antibodies or reagents developed in-house; software tied to physical hardware; and any material being sent to, or received from, a for-profit company. The University of Manchester’s contracts team states plainly that an MTA is required for the transfer of materials and/or data between the University and a third party, but explicitly carves out one exception: if the materials are available to purchase on the open market, an MTA will not be required, because that transaction is simply a purchase handled through procurement.
Special categories that raise the bar
Three categories demand extra scrutiny before any material moves, regardless of how “routine” the transfer feels:
- Human-derived material — samples covered by the UK Human Tissue Act 2004 require Human Tissue Authority (HTA) licensing checks and research ethics approval before any transfer agreement is signed.
- Genetic resources sourced internationally — transfers of genetic material obtained from a provider country after the Nagoya Protocol entered into force in 2014 trigger access-and-benefit-sharing (ABS) obligations under the Convention on Biological Diversity, independent of whatever the MTA itself says.
- Plant genetic resources for food and agriculture — material listed under the Multilateral System of the International Treaty on Plant Genetic Resources for Food and Agriculture (ITPGRFA, in force since 2004) must move under the FAO’s Standard Material Transfer Agreement (SMTA), a fixed-form contract that cannot be substituted with an institution’s own template.
Materials crossing borders may also need export-control clearance where dual-use or sensitive technology is involved, and third-party funding terms must be checked for conflicts before an MTA is countersigned — a funder’s data-sharing mandate can directly contradict a provider’s proposed use restrictions.
The decision framework: full MTA, simple letter, or no agreement
Most guidance treats “do I need an MTA” as binary. In practice, research offices work with three tiers, and choosing the wrong one either creates unnecessary friction or leaves an institution legally exposed.
| Scenario | Mechanism | Why |
|---|---|---|
| Unmodified biological material moving between two non-profit institutions that are both signatories to a master agreement | Simple implementing/loan letter | Terms are pre-agreed once; each transfer just references the master deal, e.g. under the NIH-developed Uniform Biological Material Transfer Agreement (UBMTA) |
| Proprietary, modified, human-derived, or export-controlled material; any transfer involving a for-profit party | Full negotiated MTA | Ownership, publication rights, IP on improvements, and liability all need bespoke terms |
| Material freely available for purchase on the open market, or moving within the same legal entity | No agreement (procurement or internal process only) | There is no proprietary right or cross-entity risk to allocate |
| Plant genetic resources under the ITPGRFA Multilateral System | FAO Standard Material Transfer Agreement (SMTA) | A treaty-mandated fixed form; institutions cannot substitute their own template |
The middle tier is the one most frequently mishandled. Under the UBMTA — a master agreement developed under the auspices of the US National Institutes of Health in 1995 — signatory institutions exchange unmodified biological materials using a one-page implementing letter instead of renegotiating terms each time. But even under UBMTA cover, a full bespoke MTA is still required the moment the material is human-derived, genetically modified, or hazardous, or if either party is not a signatory.
Practically, ask four questions in order:
- Is the material purchasable off the shelf? If yes, stop — use procurement, not an MTA.
- Does a signed master agreement (e.g. UBMTA) already cover both institutions and this exact material type unmodified? If yes, a loan/implementing letter is sufficient.
- Is either party for-profit, or is the material modified, human-derived, genetically modified, or export-controlled? If yes, a full negotiated MTA is required.
- Is the material a plant genetic resource under the ITPGRFA Multilateral System? If yes, the FAO SMTA applies and overrides institutional templates.
Answer-first Q&A
Do I need an MTA?
You need an MTA if you are sending or receiving tangible, non-public research material — biological samples, reagents, cell lines, or similar — to or from a different legal entity. If the material is commercially purchasable or stays within your own institution, no agreement is required; check with your contracts office before assuming either way.
What is a material transfer agreement?
A material transfer agreement is a contract between a provider and a recipient organisation that documents the material being transferred and the terms governing its ownership, permitted use, publication, and any resulting inventions. It protects both parties’ intellectual property and clarifies liability before materials change hands.
What is the standard material transfer agreement (SMTA)?
The Standard Material Transfer Agreement is the fixed-form contract required under the FAO’s International Treaty on Plant Genetic Resources for Food and Agriculture. It governs transfers of listed plant genetic resources within the treaty’s Multilateral System and cannot be replaced by an institution’s own MTA template.
Why do institutions require an MTA?
Institutions require an MTA to protect ownership of proprietary materials, define permitted research use, and settle publication and inventorship rights in advance. Without one, disputes over who owns follow-on discoveries or who may publish first become far harder to resolve after the fact.
Implications for research administrators
Getting the tier wrong has real cost on both sides. Forcing every transfer through a full negotiated MTA slows down routine science and burdens contracts teams already stretched thin. Skipping an agreement where one is legally required — particularly for human-derived or export-controlled material — exposes the institution to compliance action and jeopardises the researcher’s ability to publish or patent.
A working checklist for any incoming or outgoing transfer should confirm: the material’s category (unmodified biological, modified, human-derived, genetic resource, software, data); whether either party is for-profit; whether a signatory master agreement already applies; whether human tissue, Nagoya Protocol, or export-control obligations attach; and who at the institution holds authority to sign, since most universities restrict MTA signature to a small number of authorised contracts officers rather than the individual researcher.
As research materials increasingly cross borders and sectors — biobanks, industry-academic partnerships, international consortia — the three-tier framework above gives administrators a faster, defensible route to the right mechanism, rather than defaulting every transfer to the slowest, most conservative option. For related definitions and terminology used across research administration, see the CASRAI Dictionary and the broader research administration resource hub.
